Shifting from clinician-ordered to pathologist-initiated reflex testing for NSCLC biomarkers combines diagnosis and molecular analysis into one workflow. This operational change minimizes delays, increases testing rates, and optimizes the use of small biopsy samples, getting actionable results to oncologists faster.

Contrary to common belief, low biomarker testing rates (30-60%) are not just a community oncology problem; even academic medical centers are "guilty" of failing to test all eligible GI cancer patients. This highlights a systemic challenge in implementing personalized medicine, requiring proactive strategies at all levels of care.

To reduce treatment delays, pathologists should initiate biomarker testing reflexively. Waiting for a medical oncologist to order tests at a first visit is a system failure, wasting critical time and risking the need to retrieve archived samples.

Establishing a multi-disciplinary molecular tumour board helps operationalize biomarker strategies. This collaborative body, including oncologists and surgeons, not only interprets complex molecular data for trial matching but also collectively advocates for health insurance reimbursement for necessary tests, addressing a key practical barrier.

Unlike rare biomarkers that necessitate a 'test-and-wait' approach, IB6 is expressed in over 80-90% of NSCLC tumors. This ubiquity could make pre-screening unnecessary for drugs like Sigvotatug Vedotin, allowing clinicians to initiate targeted therapy much faster and for a broader patient population.

To overcome logistical delays, a hybrid lab testing model is effective. It uses local labs for rapid eligibility screening to accelerate patient enrollment, while simultaneously using central labs for standardized, confirmatory validation. This approach balances the need for speed with the requirement for rigorous, reliable data.

Rather than passively waiting for orders, nurses can actively check patient charts for required tests (HRD, Folate Receptor Alpha, HER2, PD-L1) and remind the physician, preventing treatment delays and ensuring access to targeted therapies.

When the FDA approves a new biomarker-linked therapy, an in-house pathology lab actively queries its historical database of all prior NGS tests to identify past cases with the relevant genetic alteration. They then proactively contact the oncologists for these patients, uncovering new treatment options that were previously unavailable.

When surgeons offer genetic testing at the point of care ("mainstreaming"), uptake is significantly higher than when patients are referred to separate genetic counselors. This model overcomes patient inertia and logistical barriers, and has been shown to improve testing rates across all socioeconomic strata.